Back to Journals » Lung Cancer: Targets and Therapy » Volume 9

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

Total article views   HTML views PDF downloads Totals
7,675 Dovepress* 6,427+ 986 7,413
PubMed Central* 1,248 191 1,439
Totals 7,675 1,177 8,852
*Since 8 November 2018

View citations on PubMed Central and Google Scholar